NCT04292899: A reported trial by Gilead Sciences
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT04292899 |
|---|---|
| Title | A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe COVID-19 |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 6, 2020 |
| Completion date | April 9, 2020 |
| Required reporting date | April 9, 2021, midnight |
| Actual reporting date | Dec. 15, 2020 |
| Date last checked at ClinicalTrials.gov | Oct. 31, 2025 |
| Days late | None |